Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.67 |
| ▸ | MAOA | P21397 | 14/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857144 | 0.92 | MAOA (0.81) | MAOBMAOA | |
| SCHEMBL27895 | 0.89 | MAOB (0.67) | MAOBMAOAHRH3 | |
| SCHEMBL4419819 | 0.86 | MAOB (0.85) | MAOBMAOA | |
| SCHEMBL31185499 | 0.86 | MAOB (0.85) | MAOBMAOAHRH3 | |
| SCHEMBL25230739 | 0.86 | MAOB (0.85) | MAOBMAOAHRH3 | |
| SCHEMBL327001 | 0.85 | MAOB (0.84) | MAOBMAOA | |
| SCHEMBL20798188 | 0.84 | MAOA (0.59) | MAOBMAOA | |
| SCHEMBL268592 | 0.83 | KDM4E (0.56) | MAOBHRH3 | |
| SCHEMBL20798290 | 0.82 | RXRB (0.66) | MAOBMAOA | |
| SCHEMBL5638876 | 0.82 | MAOB (0.86) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001844-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-0522000-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1991014674-A2 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | MAOB 603/4885MAOA 737/4885HRH3 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.